News 02.04.2019 The MAPLE study used a modified manufacturing process and demonstrated decreased intraocular inflammation Previously reported positive Phase 3 results demonstrated the potential for abicipar to be the first anti-VEGF therapy to maintain initial vision gains in all patients on a true fixed 12-week dosing interval Abicipar BLA submission to...
News 29.03.2019 Zurich-Schlieren, Switzerland, March 29, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced that the company will present new pre-clinical data highlighting the company’s immuno-oncology and DARPin® directed drug delivery (DDC) platforms at the Annual Meeting 2019...
News 25.03.2019 SCHLIEREN / ZURICH, SWITZERLAND – March 21, 2019 – Neurimmune today informed that Biogen and Eisai decided to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab in Alzheimer’s disease. Neurimmune has partnered Aducanumab with Biogen in 2007. The independent data monitoring committee advised that the trials were unlikely to...
News 13.03.2019 Schlieren (Zurich), Switzerland, March 13, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has received clearance for the Kuros TLIF cage from the U.S. Food and Drug Administration (FDA). The TLIF cage has been developed for the use with KUR-113, Kuros’s advanced Fibrin-PTH product candidate...
News 04.03.2019 ZURICH, Switzerland, March 04, 2019 – NovaGo Therapeutics AG, a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke, has closed a Series A financing round of CHF 10 million led by Pureos Bioventures and the strategic partner Neurimmune. Dr. Dominik Escher, Partner at Pureos Bioventures...